Linking Proteins to Signaling Pathways for Experiment Design and Evaluation by Farkas, Illés J. et al.
Linking Proteins to Signaling Pathways for Experiment
Design and Evaluation
Ille ´s J. Farkas
1*,A ´ da ´m Sza ´nto ´-Va ´rnagy
2, Tama ´s Korcsma ´ros
3
1Statistical and Biological Physics Research Group, Hungarian Academy of Sciences, Budapest, Hungary, 2Department of Biological Physics, Eo ¨tvo ¨sL o r a ´nd University,
Budapest, Hungary, 3Department of Genetics, Eo ¨tvo ¨sL o r a ´nd University, Budapest, Hungary
Abstract
Biomedical experimental work often focuses on altering the functions of selected proteins. These changes can hit signaling
pathways, and can therefore unexpectedly and non-specifically affect cellular processes. We propose PathwayLinker, an
online tool that can provide a first estimate of the possible signaling effects of such changes, e.g., drug or microRNA
treatments. PathwayLinker minimizes the users’ efforts by integrating protein-protein interaction and signaling pathway
data from several sources with statistical significance tests and clear visualization. We demonstrate through three case
studies that the developed tool can point out unexpected signaling bias in normal laboratory experiments and identify
likely novel signaling proteins among the interactors of known drug targets. In our first case study we show that knockdown
of the Caenorhabditis elegans gene cdc-25.1 (meant to avoid progeny) may globally affect the signaling system and
unexpectedly bias experiments. In the second case study we evaluate the loss-of-function phenotypes of a less known C.
elegans gene to predict its function. In the third case study we analyze GJA1, an anti-cancer drug target protein in human,
and predict for this protein novel signaling pathway memberships, which may be sources of side effects. Compared to
similar services, a major advantage of PathwayLinker is that it drastically reduces the necessary amount of manual literature
searches and can be used without a computational background. PathwayLinker is available at http://PathwayLinker.org.
Detailed documentation and source code are available at the website.
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Introduction
Signaling pathways regulate several cellular processes, including
cell growth, differentiation, stress response and adaptation [1,2]. In
addition, signaling pathways control cell-cell communication and
organism-level processes in the immune and hormone systems.
Malfunctions of signaling pathways may lead to ‘systems diseases’
[3], for example, cancer or diabetes. Accordingly, perturbations of
signaling proteins can non-specifically affect many cellular
processes. Altering the functions of selected genes or proteins is
a common procedure in biomedical research and can lead to the
discovery of novel molecular functions and organism-level
characteristics. Unfortunately, these modifications often induce
unexpected and unwanted changes in the normal functions of
signaling pathways. The first step towards quantifying the effects of
these signaling changes is the identification of known signaling
components among the modified proteins and their interacting
partners. Currently, most research laboratories perform this step
either by (i) time-consuming manual literature searches (requiring
expertise with signaling pathways) or (ii) a semi-automatic scan of
databases (requiring advanced programming skills). PathwayLin-
ker is meant to be an efficient alternative to both resource-
intensive approaches. It identifies the interactions linking the
queried protein(s) to signaling pathways by applying the
interaction and pathway data types selected by the user.
PathwayLinker allows experimentalists and computational biolo-
gists to quickly and systematically obtain first estimates of the
possible signaling effects of modifying single proteins or selected
groups of proteins (e.g., by microRNAs or as drug targets).
Materials and Methods
We integrated physical and genetic interaction data and
signaling pathway membership data for the nematode Caenorhab-
ditis elegans, the fruit fly Drosophila melanogaster, and humans. For the
interactions, we used small-scale and high-throughput physical
interactions from BioGRID (version 3.0.64) and STRING (version
8.3), small-scale physical, high-throughput physical, and genetic
interactions from the Worm Interactome (version 8) and DroID
(version 2010_08), and small-scale physical interactions of human
proteins from HPRD (version 5) [4–8]. Signaling pathway
reference data was compiled by integrating data from the pathway
databases KEGG (version 53.0), Reactome (version 33), and
SignaLink (version 1.0) [9–11]. In each case we mapped gene/
protein names to UniProt primary accessions, human-readable
protein names and database-specific identifiers (Flybase ID,
Wormbase ID, Ensembl gene and protein ID, etc.) with the
programmable online services of UniProt [12].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36202PathwayLinker speeds up searches and protein identifier (ID)
conversions by saving all new ID mapping results locally and
accessing these at subsequent ID mapping requests. Analysis
subroutines identify interactors and pathway member proteins
among them and compute statistical tests. Cytoscape Web [13] a
jQueryUI are used for visualization and the user interface.
To estimate the signaling effect of the queried proteins and their
first neighbor interactors, PathwayLinker tests for each signaling
pathway whether it is statistically significantly overrepresented
among the queried proteins. First, the queried proteins and their
first neighbor interactors are listed. Next, for each signaling
pathway, S, PathwayLinker counts how many (N) of these proteins
function in S. Last, the p-value of the overrepresentation of each
pathway is computed by finding the probability of observing at
least N such proteins (i.e., a hypergeometric distribution is applied).
For details, see http://pathwaylinker.org/pathway_score.
Results
The workflow
The user should first select the species (worm, fly, or human)
and enter the search terms, which can be arbitrary protein or gene
names/IDs as well as drug/compound names or DrugBank IDs
(Fig. 1.). Note that most genes/proteins have multiple identifiers.
PathwayLinker (through the UniProt synonym search API)
recognizes a large variety of name and ID types and identifies
target proteins of drugs/compounds based on DrugBank. Note
also the autocomplete feature: after typing a few letters, the user
receives a short list of possible completions. Further typing will
refine the list of suggestions. PathwayLinker has two possible
search modes: quick and advanced (Fig. 1.). In a quick search after
entering the keywords no further action is required from the user.
In this case UniProt primary accessions with the highest synonym
search scores for each entered search term are used automatically
with together the default values of all further search parameters. In
an advanced search the user can select
(1) for each search term a set of UniProt primary accessions from
the full list of accessions obtained through a UniProt synonym
search for that search term;
(2) sources of interactions (BioGrid, STRING, WI8, DroID,
HPRD [4–8]) to be used for identifying first neighbor
interactors, or group of these interactions (high-throughput
physical, small-scale physical, genetic);
(3) sources of signaling pathways (KEGG, Reactome, SignaLink
[9–11]).
Figure 1. Workflow of PathwayLinker with the C. elegans gene cdc-25.1 as an example.
doi:10.1371/journal.pone.0036202.g001
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visualizes the network of the queried proteins and their first
neighbor interactors, (ii) labels signaling pathway member
proteins, (iii) provides enrichment statistics and (iv) direct links to
external resources, and (v) has several download options. Among
the displayed proteins, signaling pathway members can be
highlighted by selecting pathway names, e.g., WNT or Notch,
from a list. It is easy to select from this list, because pathways can
be sorted and the number of member proteins participating in
each pathway is displayed. Interactions can also be further
analyzed by highlighting those present in at least one or all of the
interactively marked sources (e.g., BioGrid, HPRD). A click on any
displayed protein provides hyperlinks to UniProt, species-specific
resources (Wormbase, Flybase, Ensembl), Gene Ontology term pages
(QuickGO) and maps of the signaling pathways containing the given
protein [12,14–17]. Similarly, click on any displayed interaction to
receive hyperlinks pointing to the PubMed abstract(s) of the
article(s) containing experimental evidence for the interaction
(literature data acquired from the selected interaction databases).
To estimate the signaling effect(s) of the queried proteins and
their first neighbor interactors we provide p-values and highlight
those signaling pathways significantly that are overrepresented
among the displayed proteins as compared to all proteins in the
given species. In addition, two external resources are available for
exploring the statistically significantly overrepresented biological
functions of the analyzed protein(s): DAVID compares protein
domain structures, expression profiles and GO annotations [18],
while PharmGKB shows pharmacological properties [19].
Currently, the PathwayLinker’s report can be downloaded in
two formats: plain text and PDF. Moreover, the user may return
later to each report page by saving or receiving via e-mail its short
stable web address (URL). For computational biologists automated
programmable access is offered through an application program-
ming interface (API). All features and downloadable files are
Figure 2. Functions of the report page of PathwayLinker. All nodes (proteins) and edges (interactions) can be clicked for further information.
Proteins and interactions can be highlighted by selecting their known signaling pathways and by selecting their known interaction types,
respectively. A built-in statistical enrichment test and direct hyperlinks to analyses by external resources are also available. These allow the user to
select the most significantly enriched functions within the group of proteins made up of the queried protein(s) and its (their) interactors. The report is
available in PDF and plain text (machine readable) formats. The user can have the stable URL of the report e-mailed to a selected address.
doi:10.1371/journal.pone.0036202.g002
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corner of the page).
Examples
PathwayLinker can indicate unexpected signaling bias in
normal laboratory experiments. Consider, for example, the
protein interactors of the gene cdc-25.1 (Fig. 2.). The knock-down
of this gene is often used to sterilize C. elegans [20]: sterilized worms
are used to avoid progeny in diverse experiments. We found that
six of the nine first neighbor interactors of CDC-25.1 have central
roles in signaling pathways (EGF/MAPK, IGF, Notch, TGF, and
WNT): DAF-2 (a worm Insulin receptor), SMA-6 (a worm TGF-
beta receptor), LET-60 (RAS protein), SEM-5 (GRB2 adaptor
protein), POP-1 (transcription factor – TCF4), and GLP-1 (a
worm NOTCH receptor). Note that all six proteins are orthologs
of major human signaling proteins. Consequently, sterilizing C.
elegans by knocking down cdc-25.1 can globally affect the
organism’s signaling system and unexpectedly bias experiments.
PathwayLinker can help during the evaluation of experimen-
tally obtained phenotypes. To predict the function(s) of a gene that
has no known function so far, most genetic studies link the
observed phenotypes to the phenotypes of genes with known
functions and signaling pathways. This process requires a large
number of interactive searches in genome and interaction
databases. PathwayLinker can drastically reduce the amount of
this interactive work. As an example, consider the phenotypes of
the C. elegans gene C27F2.4 (a predicted carboxyl methylase gene
[16]), which has no known signaling pathway memberships so far.
With PathwayLinker, one can find out with reduced effort that all
observed loss-of-function phenotypes of C27F2.4 are present
among the phenotypes of the currently known interactors of
C27F2.4. Therefore, the functions of these interactors and
C27F2.4 possibly match. In more detail, high-throughput physical
experiments [6] indicated that the protein C27F2.4 interacts with
BAR-1, CLK-2 and RHA-2. Of these interactors only BAR-1, an
ortholog of human Beta-catenin, is a known signaling pathway
member (in the nematode WNT and EGF/MAPK signaling
pathways). Since BAR-1 is a key component of the WNT pathway,
we analyzed the possible relationship of C27F2.4 with the WNT
pathway in more detail. A direct link from PathwayLinker’s report
page points to the WormBase [16] fact sheet of bar-1 where 3
phenotypes (slow growth, receptor mediated endocytosis defective
and transgene expression pattern variance) out of the listed 14 are
common knock-down phenotypes of the WNT pathway. Interest-
ingly, WormBase lists these 3 WNT-phenotypes also in connection
with the loss of C27F2.4; thus, C27F2.4 is likely to function in the
WNT pathway as well. Further analysis of the other 2 interactors
of C27F2.4 (CLK-2 and RHA-2) showed that they do have the
remaining 2 known phenotypes of C27F2.4 suggesting its possible
function in processes that involve CLK-2 and RHA-2.
PathwayLinker can also identify important signaling proteins as
interactors of known human drug targets. We investigated the
known drug target protein GAP JUNCTION ALPHA-1 (GJA1;
also known as Connexin-43), which is currently not known to be a
member of any signaling pathway. Three anti-cancer drugs –
cisplatin, mercaptopurine, and methotrexate – have known effects
on GJA1. [19,21,22]. A quick analysis with PathwayLinker (using
all interaction and pathway sources) shows that GJA1 has 47
interactors that are members of 66, 9, and 5 signaling pathways
according to the pathway databases KEGG, Reactome, and
SignaLink, respectively. In our analysis we selected two major
pathways (EGF/MAPK and WNT) that are important in
development and several diseases. We found that 6 of the proteins
directly interacting with GJA1 participate in the EGF/MAPK
pathway (CSK, PRKA, PRKX, SRC and 2 major kinases of the
MAPK pathway: ERK1 and ERK5). For the WNT pathway the
analysis showed PRKA and CCND1 as direct interactors of GJA1,
and 3 more key signaling proteins: CASEIN KINASE I
(CSNK1D), BETA-CATENIN (CTNNB1), and a major tran-
scription factor of the WNT pathway, LEF1. Interestingly, PRKA
(Protein kinase A-anchoring protein; also known as AKAP)
participates in both pathways, which increases its importance as
a multi-pathway protein among the first neighbors of GJA1. Note
that neither PharmGKB nor DrugBank [19,23], two major
pharmaceutical databases, list these 2 affected pathways for
GJA1. In summary, for the drug target protein GJA1, that is
known to be cancer-related, PathwayLinker predicts novel
signaling pathway memberships. These pathway memberships
can be a source of possible side effects when targeting GJA1.
Discussion
In biomedical research modified genes/proteins often contribute to
the discovery of novel molecular functions and organism-level
characteristics. However, these modifications can induce unwanted
side effects, often through altered signaling pathways. We have
developed PathwayLinker, an online tool for estimating the possible
signaling effect(s) of selected proteins and their first neighbor
interactors. We have demonstrated that PathwayLinker can support
the design and evaluation of experiments. First, if a gene or a protein
is manipulated (e.g., by knockout or knockdown), then the developed
online tool can provide a quick first estimate of how this manipulation
may affect intracellular signaling and cause unwanted phenotypes.
Conversely, if a protein modification (e.g., gene modification or drug
treatment) causes an unexpected phenotype, then PathwayLinker can
help to identify which interactor(s) and signaling pathway(s) are most
likely to have contributed to that phenotype.
The recently launched online tools CentiBiN [24], NeAT [25],
and MTOM [26] focus on advanced network analyses by
applying, e.g., centrality measures, randomization, and topological
overlap, respectively. On the other hand, PathwayLinker is more
similar to DAVID [18] and BioProfiling.de [27], which focus on
the functional analysis of gene lists and include signaling pathway
membership and interaction data. Compared to these two, the
uniqueness of the PathwayLinker lies in its ability to analyze the
pathway memberships of the first neighbor interactors in a
targeted way and to perform statistical tests that can evaluate even
small sets of proteins (not only large gene lists).
Future plans for extending PathwayLinker are: (i) including
regulatory and metabolic pathways; (ii) allowing users to upload
their own pathways; and (iii) linking result sets to further external
web services. The pathway and interaction databases will be
updated every 12 months. Comments or suggestions are welcome.
Contact information, a feedback form and detailed documentation
are available at http://PathwayLinker.org.
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